Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1

Interventions

pembrolizumab 118Carboplatin 101Paclitaxel 62Cisplatin 56Gemcitabine 55Pemetrexed 52Bevacizumab 49Docetaxel 44Fluorouracil 39Oxaliplatin 37Dexamethasone 34130-nm albumin-bound paclitaxel 33atezolizumab 32Leucovorin 32Cetuximab 31durvalumab 26Nivolumab 25Capecitabine 25Rituximab 24Prednisone 24Fulvestrant 23Cyclophosphamide 23Lenalidomide 22enzalutamide 21venetoclax 20Irinotecan 19Letrozole 18pomalidomide 16apalutamide 16daratumumab 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × elotuzumab × 30 days × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06158841 2026-06-05

CERVINO

AbbVie

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

NCT06208150 2026-06-05

MonumenTAL-6

Janssen Research & Development, LLC

Phase 3 Recruiting
795 enrolled
Plasma cell

Multiple Myeloma

NCT07555938 2026-05-27

CEVOLUTION

Hoffmann-La Roche

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡